Boehringer Ingelheim will cap out-of-pocket costs for its inhaler products at $35 per month starting in June. 

Trials for experimental HIV vaccines have been fruitless for the last two decades, but recent scientific advances are spurring optimism among researchers, NBC News reported March 6. 

On March 7, Franklin, Tenn.-based Community Health Systems became the first hospital system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co.

An FDA advisory panel has unanimously recommended the agency approve a trivalent, rather than quadrivalent, flu vaccine for use next season.

Merck's cancer drug Keytruda is expected to be the top-selling drug globally in 2024, according to data published by Statista.

The FDA on March 5 cleared the Dexcom Stelo Glucose Biosensor System for use, making it the first continuous glucose monitoring device to be available over the counter.

It has been 44 years since work toward a viable vaccine for respiratory syncytial virus began. But, after the inaugural roll-out of an RSV vaccine for older adults and a maternal vaccine to protect infants during the 2023-2024 viral season,…

A common medication used to manage and treat HIV is becoming increasingly resistant, according to a report from the World Health Organization.

Anecdotally, patients on a popular class of weight loss drugs known as glucagon-like peptide receptor agonists are reporting another potential benefit experts are optimistic about: reduced cravings for alcohol. 

Mark Cuban Cost Plus Drug Co. plans to begin manufacturing epinephrine and norepinephrine this week at its 22,000-square-foot drug facility in Dallas, Mr. Cuban confirmed to Becker's on March 5.